The purpose of this study is to provide continued access to treatment with pelabresib for patients who previously received pelabresib in a parent study and to continue collecting safety and efficacy information. By collecting efficacy information, the study team monitors if pelabresib helps the patient with their disease. Additionally, survival follow-up data will be collected. Survival follow-up collects information on the patient's leukemia-free survival and overall survival status (life span) during and after the treatment is ended. If a patient stopped pelabresib treatment on the parent study for any other reason than participation in this study, they will not receive further pelabresib treatment, but they can enter the study for survival-follow up only.

开始日期2024-08-13

申办/合作机构

Constellation Pharmaceuticals, Inc.

NCT05391022 / Completed临床1期

A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies

Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies

开始日期2021-07-20

申办/合作机构

Constellation Pharmaceuticals, Inc.

NCT04603495 / Active, not recruiting临床3期

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

开始日期2021-04-09

申办/合作机构

Constellation Pharmaceuticals, Inc.

100 项与 Pelabresib 相关的临床结果

登录后查看更多信息

100 项与 Pelabresib 相关的转化医学

登录后查看更多信息

100 项与 Pelabresib 相关的专利（医药）

登录后查看更多信息

项与 Pelabresib 相关的文献（医药）

2024-05-01·American journal of hematology

New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors

Letter

作者: Tefferi, Ayalew ; Gangat, Naseema

Ruxolitinib in combination with navitoclax or pelabresib in myelofibrosis: activity in JAKi-naïve patients.

2024-04-12·EXPERT OPINION ON PHARMACOTHERAPY

Advances in pharmacotherapy for myelofibrosis: what is the current state of play?

Review

作者: Tiribelli, Mario ; Morelli, Gianluca ; Bonifacio, Massimiliano

INTRODUCTION:

The introduction of the first JAK inhibitor (JAKi) ruxolitinib 10 years ago represented a pivotal advancement in myelofibrosis (MF) treatment, mostly in terms of spleen and symptoms response. Nowadays three more JAKi, fedratinib, pacritinib, and momelotinib, are available for both ruxolitinib-resistant and naïve patients. Moreover, many drugs are currently being investigated, both alone and in combination with JAKi.

AREAS COVERED:

In this review we discuss the long-term data of ruxolitinib and more recent evidence coming from clinical trials of fedratinib, pacritinib, and momelotinib, used as first- or second-line MF therapy. More, focus is set on data from non-JAKi drugs, such as the quite extensively studied BET-inhibitors (pelabresib) and BCL-inhibitors (navitoclax), novel target therapies, and drugs aimed to improve anemia, still representing a major determinant of reduced survival in MF.

EXPERT OPINION:

It's now evident that JAKi monotherapy, though clinically effective, is rarely able to change MF natural history; novel drugs are promising but long-term data are inevitably lacking. We feel that soon MF treatment will require clinicians to select the most appropriate JAKi inhibitor, based on patient characteristics, associating either front-line or in case of early suboptimal response, non-JAKi drugs with the aim to pursue disease modification.

2024-03-20·Leukemia & lymphoma

Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies

Article

作者: Fathi, Amir T. ; Colak, Gozde ; Fusco, Andrea ; Harb, Wael A. ; Stein, Eytan M. ; Mangan, James K.

Pelabresib (CPI-0610), a BET protein inhibitor, is in clinical development for hematologic malignancies, given its ability to target NF-κB gene expression. The MANIFEST phase 1 study assessed pelabresib in patients with acute leukemia, high-risk myelodysplastic (MDS) syndrome, or MDS/myeloproliferative neoplasms (MDS/MPNs) (NCT02158858). Forty-four patients received pelabresib orally once daily (QD) at various doses (24-400 mg capsule or 225-275 mg tablet) on cycles of 14 d on and 7 d off. The most frequent drug-related adverse events were nausea, decreased appetite, and fatigue. The maximum tolerated dose (MTD) was 225 mg tablet QD. One patient with chronic myelomonocytic leukemia (CMML) showed partial remission. In total, 25.8% of acute myeloid leukemia (AML) patients and 38.5% of high-risk MDS patients had stable disease. One AML patient and one CMML patient showed peripheral hematologic response. The favorable safety profile supports the ongoing pivotal study of pelabresib in patients with myelofibrosis using the recommended phase 2 dose of 125 mg tablet QD.CLINICAL TRIAL REGISTRATION: NCT02158858.

项与 Pelabresib 相关的新闻（医药）

2024-11-25

·GlobeNewswire-Health Care

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presentedPipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers Basel, November 25, 2024 – Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition and the 2024 San Antonio Breast Cancer Symposium® (SABCS). “By prioritizing research in areas of greatest medical need and focusing on earlier stages of disease, we aim to change the treatment paradigm for people who require additional treatment options,” said Jeff Legos, Executive Vice President, Global Head of Oncology Development, Novartis. “The new data being presented at ASH and SABCS underscore our commitment to patients with cancer or blood disorders and follow new, expanded indications for Scemblix and Kisqali along with recent updates in national treatment guidelines." In addition to late-breaking data, Novartis will host an art gallery-style exhibit at SABCS featuring personal letters and stories written by people impacted by breast cancer, sharing their raw, authentic perspectives on aspects of the breast cancer journey. These letters and stories aim to uplift patients, encourage reflection, and demonstrate strength and unity among the breast cancer community. Key abstracts accepted by ASH include: Medicine or Disease State      Abstract Title      Abstract Number/ Presentation Details       Scemblix®Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study Abstract #475Oral PresentationSunday, December 89:30 – 11:00 AM PTScemblix   Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI) Abstract #479Oral PresentationSunday, December 89:30 – 11:00 AM PTScemblix Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study Abstract #4526Poster PresentationMonday, December 96:00 – 8:00 PM PTScemblix Treatment with Asciminib as a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP)– a Chart Review Study in the United States Abstract #3812Poster PresentationSunday, December 86:00 – 8:00 PM PTIanalumab (VAY736)A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3 Abstract #710Oral PresentationMonday, December 910:30 AM – 12:00 PM PTRapcabtagene autoleucel (YTB323)Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update Abstract #67Oral PresentationSaturday, December 79:30 – 11:00 AM PTFabhalta®Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials Abstract #4079Poster PresentationMonday, December 96:00 – 8:00 PM PTFabhalta The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial Abstract #4087Poster PresentationMonday, December 96:00 – 8:00 PM PTFabhalta Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden Abstract #2327Poster PresentationSaturday, December 75:30 – 7:30 PM PTPelabresib (CPI-0610)Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with MyelofibrosisAbstract #3178Poster PresentationSunday, December 86:00 PM - 8:00 PM PT Key abstracts accepted by SABCS include: Medicine or Disease State      Abstract Title      Abstract Number/ Presentation Details       Kisqali® (ribociclib)* Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2- early breast cancer (EBC) Abstract #P4-09-22Poster SessionThursday, December 125:30 – 7:30 PM CST Kisqali     Impact of ribociclib dose reduction on efficacy in patients with hormone receptor– positive/human epidermal growth factor receptor 2–negative (HR+/HER2-) early breast cancer (EBC) in NATALEE Abstract #P1-11-16Poster Session Wednesday, December 1112:30 – 2:00 PM CSTKisqali Risk of recurrence in real-world (RW) NATALEE- and monarchE-eligible populations of patients with HR+/HER2- early breast cancer (EBC) in an electronic health record (EHR)-derived database Abstract #P2-12-02Poster SessionWednesday, December 115:30 – 7:00 PM CST Kisqali Tolerability of First-Line (1L) Treatment (tx) With Ribociclib (RIB) for Metastatic Breast Cancer (MBC) Using 2 Large US Data Sources Abstract #P3-10-14Poster SessionThursday, December 1212:30 – 2:00 PM CST Kisqali Impact of body mass index (BMI) on the safety and efficacy of ribociclib (RIB) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): pooled analysis of the MONALEESA (ML)-2, -3, and -7 trials Abstract #P2-09-20Poster SessionWednesday, December 115:30 – 7:00 PM CST Kisqali First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2- advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression Abstract #PS2-06Poster PresentationThursday, December 127:00 – 8:30 AM CST Product Information     For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # * Kisqali was developed by Novartis under a research collaboration with Astex Pharmaceuticals. Novartis Media RelationsE-mail: media.relations@novartis.com Central North America Anja von Treskow+41 79 392 9697Michael Meo+1 862 274 5414Anna Schäfers+41 79 801 7267 SwitzerlandSatoshi Sugimoto +41 79 619 2035 Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com Central North America Isabella Zinck+41 61 324 7188Sloan Simpson+1 862 345 4440Nicole Zinsli-Somm+41 61 324 3809Jonathan Graham+1 201 602 9921Imke Kappes+41 61 324 8269Parag Mahanti+1 973 876 4912

临床3期临床结果临床2期ASH会议

2024-11-21

·Endpoints

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed to Endpoints News on Thursday. And Novartis is not done yet. It is still on the lookout for bolt-on M&A opportunities — but don’t expect them to go higher than $3 billion. “That’s not that we couldn’t do a little bit bigger, but that’s the majority of the available target companies, if you will,” Novartis CFO Harry Kirsch told the media ahead of its investor event in London on Thursday. CEO Vas Narasimhan added that a lot of M&A from the recent past has been in the $1 billion to $2 billion range, pointing to its acquisitions of Mariana Oncology and KateTx. Over the past eight years, it made $5 billion to $10 billion deals only “occasionally” because of valuation considerations and “financial discipline,” he added. Novartis will take on KateTx’s pipeline of preclinical candidates in Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. The San Diego biotech’s gene therapy tech features adeno-associated virus capsids that deliver their payloads into specific tissues to avoid off-target issues such as hepatic side effects. In June 2023, it said that it was partnering with Astellas on a neuromuscular disease called X-linked myotubular myopathy. Novartis revealed its purchase of KateTx ahead of its Meet Novartis Management event in London that was intended to reassure investors its pure-play strategy is bearing fruit now and in the next several years. A key part of its growth strategy is more M&A as “replacement power,” with the company facing the loss of exclusivity for key drugs such as Entresto , Kirsch said. When asked if changes to the Federal Trade Commission could lead to Novartis raising its M&A budget, Narasimhan said the FTC is not a major driver of its decisions. As a part of its reorg, the company zeroed in on four therapeutic spaces: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. “Preclinical, Phase 1, Phase 2 area — that’s the opportunity where we can step in” and Novartis can add value to the acquired company, Narasimhan said, adding that it’s challenging to “find synergies, harder to justify” with later-stage candidates. Narasimhan said that when it bought MorphoSys for $2.9 billion, its lead oncology candidate , pelabresib, was in an ongoing Phase 3 trial. “We saw the opportunity in an area of myelofibrosis that we’ve been in for a long period of time, and we took a bet on an ongoing clinical trial,” he said, adding that if it had waited for the late-stage readout, the purchase price would have been “double at least.” But that bet on MorphoSys led to the company taking an $800 million impairment hit just months after the deal closed due to emergent malignancies. “In this case, it didn’t go our way,” he said, nonetheless noting the company’s overall M&A track record . As for pelabresib, the company’s next update should come in the second half of next year. Narasimhan said it is monitoring patients until the middle of next year. “We are also planning to conduct additional studies to look at certain subpopulations of myelofibrosis patients where pelabresib could have a better benefit-risk profile. So I think all of that will take us at least until 2027 — it might take longer, depending on the safety topic,“ he added.

并购临床3期临床2期基因疗法临床1期

2024-11-02

·药事纵横

减值8亿美元！诺华29亿美元收购药物受挫

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。 10月29日，诺华公布2024年第三季度业绩并披露其29亿美元收购MorphoSys的赌注遇到危机。财报概述诺华财报显示：前三季度总收入371.64亿美元，同比增长11%；净收入91.19亿美元，同比增长62%；核心业务收入146.35亿美元，同比增长20%；研发投入为71.80亿美元，同比下降19%。其中第三季度收入128.23亿美元，同比增长10%；净收入为31.85亿美元，同比增长121%；研发投入为23.92亿美元，同比下降40%。在核药领域，诺华同时拥有Lutathera和Pluvicto两款畅销产品并在持续拓展适应症。2024Q3 Lutathera收入1.9亿美元，同比增长19%；前三季度Pluvicto总收入5.34亿美元，同比增长17%。 2024Q3 Pluvicto收入3.86亿美元，同比增长50%；前三季度Pluvicto总收入10.41亿美元，同比增长47%。目前诺华已提交Pluvicto用于二线治疗PSMA阳性mCRPC的上市申请。该适应症获批后，Pluvicto的全年销售额有望突破新高。收购减值此外，诺华公司在其第三季度财报中表示，在完成对MorphoSys公司29亿美元的收购交易仅五个月后，公司记录了一笔8亿美元的收购减值。这项收购的重点是MorphoSys公司的骨髓纤维化药物候选物Pelabresib，收购基于MorphoSys公司的骨髓纤维化药物候选物pelabresib 3期临床试验MANIFEST-2的顶线结果达到了主要终点。但今年7月，Pelabresib在III期MANIFEST-2研究中的结果好坏参半，而且有未经证实的报道显示其存在潜在安全风险。早在今年4月，STAT news引用参与Pelabresib 3期研究的匿名人员信息，有“多例”患者在接受Pelabresib治疗后，从骨髓纤维化“迅速进展”为更具侵袭性的急性髓性白血病（AML）。3期研究中的212名患者中6名患者进展为AML，而对照组只有2名。MorphoSys已经向FDA通报了这些安全信号，监管机构正在监控情况，并已向参与该研究的医生发出警告。这使该公司为收购的pelabresib申请批准的计划推迟数年，因为它需要更长时间地跟踪患者以应对对于突发恶性肿瘤的担忧。该公司最初希望今年获得批准用于骨髓纤维化治疗。诺华周二还披露了三项二期研究计划：一种用于多发性骨髓瘤的BCMA细胞疗法，名为durcabtagene autoleucel；一种用于高血压和心力衰竭的候选药物 XXB750；一种用于肺肉瘤病的IL-17抑制剂，名为CMK389。目前公司共有105条研发管线。参考资料： [1]公司公告 [2]https://endpts.com -END- 2025CMC-CHINA药博会 • 展位火热预定中！

并购临床3期财报临床结果临床成功

100 项与 Pelabresib 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
血液肿瘤	临床3期	美国	Constellation Pharmaceuticals, Inc.	2024-08-13
实体瘤	临床3期	美国	Constellation Pharmaceuticals, Inc.	2024-08-13
骨髓纤维化	临床3期	美国	MorphoSys AG	2022-01-30
原发性血小板增多症后骨髓纤维化	临床3期	美国	Constellation Pharmaceuticals, Inc.	2021-04-09
原发性血小板增多症后骨髓纤维化	临床3期	澳大利亚	Constellation Pharmaceuticals, Inc.	2021-04-09
原发性血小板增多症后骨髓纤维化	临床3期	奥地利	Constellation Pharmaceuticals, Inc.	2021-04-09
原发性血小板增多症后骨髓纤维化	临床3期	比利时	Constellation Pharmaceuticals, Inc.	2021-04-09
原发性血小板增多症后骨髓纤维化	临床3期	加拿大	Constellation Pharmaceuticals, Inc.	2021-04-09
原发性血小板增多症后骨髓纤维化	临床3期	捷克	Constellation Pharmaceuticals, Inc.	2021-04-09
原发性血小板增多症后骨髓纤维化	临床3期	法国	Constellation Pharmaceuticals, Inc.	2021-04-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04603495 (MANIFEST-2, CTgov)	临床3期	原发性血小板增多症后骨髓纤维化 \| 真性红细胞增多症后骨髓纤维化 \| 原发性骨髓纤维化	430	Ruxolitinib+Pelabresib (Pelabresib + Ruxolitinib)	壓鹽築襯醖醖夢艱廠鹹(鏇鏇範鹹蓋憲觸廠襯廠) = 夢壓選選鑰鏇醖範夢窪觸觸夢糧膚範築構憲選 (憲鑰鏇築選繭繭艱艱顧, 願齋蓋鏇餘蓋繭範遞鬱 ~ 積壓糧鹽襯鑰製艱膚醖) 更多	-	2024-10-28
				Placebo+Ruxolitinib (Placebo + Ruxolitinib)	壓鹽築襯醖醖夢艱廠鹹(鏇鏇範鹹蓋憲觸廠襯廠) = 鬱夢醖網範網齋壓膚願觸觸夢糧膚範築構憲選 (憲鑰鏇築選繭繭艱艱顧, 築鹽廠蓋繭網獵衊廠鹹 ~ 鏇夢製壓觸選願顧獵鹽) 更多
SOHO2024	N/A	骨髓纤维化	-	Pelabresib+ruxolitinib	窪窪選願積糧積襯艱鑰(鹹觸遞簾衊網憲鹹糧艱) = 43.9% vs 54.7% 鹹範鹽鏇簾衊願糧選窪 (衊艱襯壓遞衊衊襯鬱衊 ) 更多	-	2024-09-04
				Placebo+ruxolitinib
NCT04603495 (MANIFEST-2, ASCO2024) 人工标引	临床3期	骨髓纤维化	430	Pelabresib + Ruxolitinib	醖夢觸衊餘網願製鑰觸(選淵襯鹽築蓋鏇鏇壓獵) = 簾齋憲衊齋製遞鹹繭選範淵蓋鑰製壓鹽壓鬱獵 (醖築積夢膚繭鏇廠淵淵 ) 更多	积极	2024-05-24
				Placebo + Ruxolitinib	醖夢觸衊餘網願製鑰觸(選淵襯鹽築蓋鏇鏇壓獵) = 艱築夢願選廠獵齋衊憲範淵蓋鑰製壓鹽壓鬱獵 (醖築積夢膚繭鏇廠淵淵 ) 更多
NCT04603495 (MANIFEST-2, EHA2024) 人工标引	临床3期	骨髓纤维化 JAK2	-	Pelabresib+Ruxolitinib	衊鬱衊顧膚選簾構積夢(膚鹽餘構積齋鬱鹽積廠) = 膚構窪蓋淵餘簾窪鹹鬱願衊壓衊廠鬱獵簾簾鑰 (鹽築獵鑰廠醖餘鹹構鑰, -36.5 ~ -31.1) 更多	积极	2024-05-14
				Placebo+Ruxolitinib	衊鬱衊顧膚選簾構積夢(膚鹽餘構積齋鬱鹽積廠) = 顧範鏇蓋獵餘觸網襯鹹願衊壓衊廠鬱獵簾簾鑰 (鹽築獵鑰廠醖餘鹹構鑰, -23.7 ~ -17.9) 更多
NCT02158858 (MANIFEST, Pubmed) 人工标引	临床1期	髓系肿瘤 Protein Expression Markers	44	Pelabresib	衊鹹製築積鹹積製淵糧(願顧壓鏇顧遞膚憲鬱膚) = nausea, decreased appetite, and fatigue 遞齋糧蓋鏇網網壓壓鹽 (蓋顧鏇範廠獵艱網遞築 ) 更多	积极	2024-01-23
				Pelabresib (acute leukemia)
NCT04603495 (MANIFEST-2, Corporate Publications) 人工标引	临床3期	原发性骨髓纤维化	430	Pelabresib + Ruxolitinib	範齋築憲襯鏇鹹餘憲淵(膚鏇積遞淵繭醖餘遞餘) = 範遞簾選築醖鑰鑰衊網構鑰鏇鹹鑰網壓夢範蓋 (築鹹淵糧膚糧襯鑰艱壓 ) 达到更多	积极	2023-11-20
				Placebo + Ruxolitinib	範齋築憲襯鏇鹹餘憲淵(膚鏇積遞淵繭醖餘遞餘) = 構製鹽簾餘範鹹獵膚廠構鑰鏇鹹鑰網壓夢範蓋 (築鹹淵糧膚糧襯鑰艱壓 ) 达到更多
NCT02158858 (MANIFEST, EHA2023)	临床2期	急性髓性白血病 \| 血小板减少症 \| 血液肿瘤 ... 更多	84	PELA + RUX	繭繭衊蓋遞襯齋範築醖(選網築選願製選鏇窪選) = 製範壓蓋願繭膚醖遞觸積鑰餘遞夢壓遞蓋憲蓋 (鑰願獵夢襯醖遞遞繭齋 ) 更多	-	2023-06-08
NCT02158858 (MANIFEST, EHA2023)	临床2期	原发性骨髓纤维化追加	87	PELA + RUX	簾遞鑰糧鹹顧顧糧遞積(糧願選艱製製選鏇夢築) = 壓夢鏇鹽鏇網窪製築廠網淵積鹹艱選鹽鹹簾鏇 (網憲鏇餘鬱憲夢鏇觸淵 ) 更多	-	2023-06-08
NCT02158858 (ASCO2023) 人工标引	临床1/2期	原发性血小板增多症	20	Pelabresib 225mg	鏇糧繭顧衊餘窪齋願簾(獵鬱鹹淵醖遞襯淵顧膚) = 遞餘膚選壓艱鏇膚觸簾選鏇艱餘繭構鹽顧選積 (製製膚網簾鬱鹽鏇簾鬱 ) 更多	积极	2023-05-31
NCT02158858 (MANIFEST, Pubmed)	临床2期	原发性骨髓纤维化	84	Pelabresib and Ruxolitinib	繭築壓鹹繭願網廠糧鹽(醖壓遞淵糧淵簾觸獵襯) = 繭製餘衊憲願網遞餘夢鏇鏇膚築遞齋積繭積醖 (積窪窪積顧範獵願窪網 ) 更多	-	2023-03-07